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Abstract: Chronic Obstructive Pulmonary Disease (COPD) is a highly heterogeneous condition 20 
projected to become the third leading cause of death worldwide by 2030. To better characterize this 21 
condition, clinicians have classified patients sharing certain symptomatic characteristics, such as 22 
symptom intensity and history of exacerbations, into distinct phenotypes. In recent years, the growing 23 
use of machine learning algorithms, and cluster analysis in particular, has promised to advance this 24 
classification through the integration of additional patient characteristics, including comorbidities, 25 
biomarkers, and genomic information. This combination would allow researchers to more reliably 26 
identify new COPD phenotypes, as well as better characterize existing ones, with the aim of 27 
improving diagnosis and developing novel treatments. Here, we systematically review the last decade 28 
of research progress, which uses cluster analysis to identify COPD phenotypes. Collectively, we 29 
provide a systematized account of the extant evidence, describe the strengths and weaknesses of the 30 
main methods used, identify gaps in the literature, and suggest recommendations for future research.  31 
Keywords: chronic respiratory disease, subtypes, statistical analysis   32 
Introduction 33 
Chronic Obstructive Pulmonary Disease (COPD) is a group of lung diseases, such as emphysema, 34 
chronic bronchitis, and asthma, that cause breathing difficulties due to inflammation of the lungs and 35 
narrowing of the airways. Typical symptoms of COPD include breathlessness, a persistent cough with 36 
phlegm, frequent chest infections, and wheezing. Its main causes are smoking, which accounts for 37 
almost 90% of cases, occupational exposure to dust and fumes, and air pollution [1]. COPD 38 
represents one of the most common respiratory diseases, and it is projected to become the third 39 
leading cause of death worldwide by 2030 [2], principally because of difficulties in early, accurate 40 
diagnosis.  41 
To better characterize COPD and improve diagnosis, the extant research has identified 42 
different patient phenotypes (i.e., the common clinical characteristics shared by patients affected by 43 
COPD). These phenotypes are usually assessed through clinical examinations, generally following 44 
the recommendations provided by the Global Obstructive Lung Disease initiative (GOLD) [3]. 45 
Specifically, GOLD classifies COPD patients into four phenotype-like categories according to a 2x2 46 
matrix structured along the dimensions of symptoms and history of exacerbations (Table 1).  47 
[Table 1 about here] 48 
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Whilst beneficial in guiding clinical practice, this and other forms of COPD classification are 49 
often in need of stronger statistical support with respect to their predictive ability regarding clinically 50 
meaningful outcomes, such as mortality and response to treatment [4]. For instance, a large 51 
prospective study (n=12,108 patients) recently showed that COPD patients receiving maintenance 52 
therapy were similarly distributed across the four GOLD phenotypes when compared to patients who 53 
received a target treatment [5]. Likewise, the proportion of comorbidities and rate of exacerbations 54 
reported across the COPD groups were similar for both cohorts, suggesting a limited discriminatory 55 
ability of these phenotypes [5].  56 
To address this issue, research has increasingly called for the integration of other 57 
determinants, such as physiological characteristics (e.g., age, body mass index, waist circumference) 58 
[6-16,18], comorbidities (e.g., diabetes, cardiovascular diseases) [6,8,10,13,16,17,19], pulmonary 59 
function tests [7,8,11-16,19],biomarkers [6,19], and genetic variants [7], as valuable information to 60 
facilitate a more comprehensive characterization of the distinctive biological nature of COPD 61 
phenotypes, thereby promising to improve their predictive ability for clinically relevant outcomes. In 62 
particular, with sustained progress in applying machine learning algorithms to medicine, research has 63 
recently begun to put forward the powerful method of clustering – a machine learning method, which 64 
allows researchers to find structures in the data so that the elements of the same cluster (i.e., a 65 
phenotype) are more similar to each other than to those from different clusters [20], with the aim of 66 
integrating patients’ information and identifying patterns of association that can characterize COPD 67 
phenotypes more precisely.  68 
Yet, at present, there is still little evidence-based information available that both systematizes 69 
current knowledge on cluster analysis for COPD phenotype characterization and pinpoints the core 70 
benefits and limitations of the different approaches. Here, we aim to tackle this gap by reviewing the 71 
last decade of research, which uses cluster analysis to identify clinically meaningful COPD 72 
phenotypes. In the following sections of this article we describe our search strategy, synthetize the 73 
characteristics of the articles retrieved (e.g., study design, population, phenotypes’ features), and 74 
provide recommendations aimed at improving the use and performance of these methods in future 75 
research and clinical practice. 76 
2 
 
Search strategy and selection criteria 77 
In keeping with PRISMA guidelines, we conducted our search through a systematic consultation of 78 
the Medline PubMed, Cochrane Library, Scopus, and Web of Science (Figure 1) databases. 79 
[Figure 1 about here] 80 
We also hand-searched the reference lists of the retrieved articles. Additionally, we searched articles 81 
in leading pulmonary and respiratory medicine scholarly outlets to specifically include journals such as 82 
The Lancet Respiratory Medicine and The American Journal of Respiratory and Critical Care 83 
Medicine, among others.  84 
Briefly, we tailored the search to probe for overarching concepts and relations pertaining to the 85 
domains of machine learning and COPD phenotypes. Specifically, we searched for studies that used 86 
cluster analysis to identify COPD phenotypes by using the MeSH keywords “COPD”, “phenotypes”, 87 
“cluster analysis”, “clustering” and “machine learning” as well as their possible variants and 88 
combinations. Moreover, we aimed to search for articles in which the COPD phenotypes reported 89 
were validated by clinically meaningful outcomes, eg, mortality, exacerbations, and response to 90 
therapy. We also searched for ongoing registered studies relevant to our research question, including 91 
NOVELTY [21], SPIROMICS [22] and the BigCOPData [23] project, which, whilst informative to the 92 
overall picture, were not individually retained in our analysis because their final results have yet to be 93 
fully disclosed. 94 
Our search resulted in 117 articles published mainly in English and covering the period between 2003 95 
and 2019. After excluding duplicates, we screened 113 papers to select unambiguous publications of 96 
relevant research. Hereby, 65 articles were excluded because they were not relevant to COPD 97 
phenotypes and/or machine learning methods, while 34 studies were excluded because the COPD 98 
phenotypes reported had not been validated with clinically meaningful outcomes.  99 
Fourteen studies that satisfied our inclusion/exclusion criteria were retained in this review. Next, we 100 
present the entire body of retrieved studies, focusing in particular on the population characteristics, 101 
study design, sample size, the derived COPD phenotypes, and the clinical outcomes against which 102 
the phenotypes were validated of the articles respecting our inclusion criteria (Table 2). Moreover, we 103 
highlighted important inputs that we appreciated from the studies excluded from our systematic 104 
analysis, as well as specific phenotypes observed in the Evaluation of COPD Longitudinally to Identify 105 
Predictive Surrogate End-points (ECLIPSE) [24] study. 106 
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[Table 2 about here] 107 
Findings   108 
Studies respecting inclusion criteria for review  109 
Populations  110 
The sample size varied considerably across studies, spanning from 65 [18] to 30,961 patients [6].The 111 
majority of the retrieved works involved multi-centre, observational cross-sectional cohorts across the 112 
world (e.g., Italy, France, Spain, Belgium, United Kingdom, Korea, Japan, New Zealand, China). Data 113 
were collected from university hospitals, tertiary care, and pulmonary rehabilitation settings. This 114 
variability may explain the high variation in sample sizes. For instance, the largest study [6] (ie, 115 
CALIBER) covered a longitudinal cohort for a period of 18 years. This cohort comprised the data of 116 
electronic health records from three UK national resources: the Clinical Practice Research Datalink 117 
(CPRD), the Hospital Episode Statistics (HES), and information on cause-specific mortality from the 118 
Office for National Statistics (ONS). The second largest study [7] was based on the Genetic 119 
Epidemiology of COPD (COPDGene) and aimed to investigate the genetic factors responsible for 120 
COPD development. Moreover, similar to CALIBER [6], Burgel et al [8] combined three national 121 
COPD cohorts from France and Belgium as well as one independent cohort from the COPD Cohorts 122 
Collaborative International Assessment (3CIA) initiative. Two other relatively large studies, each with 123 
over 1,000 patients, were carried out in Asia. One was based on the Korean COPD subgroup multi-124 
centre cohort [9] and the other one [10] included out-patients of universities’ pulmonary clinics and 125 
referral hospitals in 13 Asian cities.  126 
Importantly, despite the diverse ethnic backgrounds of the populations of these studies, the identified 127 
COPD phenotypes were rather consistent across studies, including elements of asthma-COPD 128 
overlaps, comorbidities, and obesity, amongst others. 129 
Clinical Outcomes 130 
A core characteristic shared among the reviewed studies is that all COPD phenotypes were validated 131 
by clinically meaningful outcomes, such as exacerbations, health-related quality of life, mortality rate, 132 
and responses to therapy. These phenotypes were cross-validated in a large (n=2,746) three-year 133 
observational multi-centre international study – the Evaluation of COPD Longitudinally to Identify 134 
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Predictive Surrogate End-points (ECLIPSE) [24]. In this study, a cross-sectional analysis of the 135 
baseline data showed that patients with COPD had more frequent comorbidities, especially 136 
cardiovascular ones, when compared to controls [25]. It also showed that males with COPD were 137 
more susceptible to cardiovascular comorbidity than females; moreover, in Pikoula et al [6], patients 138 
with comorbid cardiovascular disease and diabetes were characterized by high hospital admission 139 
rates for acute exacerbations of COPD (AECOPD) and were reported as being more likely to die of 140 
cardiovascular disease.  141 
Building on these results, subsequent works [26,27] identified phenotypes of patients with frequent 142 
(i.e., two or more per year) exacerbations as well as patients with a rapid decline in their lung function. 143 
The latter evidence [27] was further extended by a five-year longitudinal study that classified patients 144 
into three groups: fast decline, slow decline, and stable patterns [28]. The latter work showed that the 145 
only factor significantly associated with a fast decline of FEV1 (Forced Expiratory Volume in 1 146 
second) was the severity of the emphysema. Moreover, 25% of the cohort was represented by the so-147 
called “asthma-COPD overlap,” or ACO, in which patients are characterized by having more 148 
exacerbations and more frequent comorbidities than in other rapid-decline COPD types [29].  149 
Features of COPD Phenotypes 150 
We found substantial heterogeneity in both the numbers and features of phenotypes presented in the 151 
literature. The number of COPD phenotypes identified varied from two to five, the most frequently 152 
reported being three [10,11,13-15] and five [6,8,16,17,19].   153 
Intriguingly, the features pertaining to the three most reported phenotypes varied across studies. For 154 
instance, phenotypes were characterized by patients having frequent exacerbations and a fast decline 155 
in lung function and in quality of life [10], but also by patients of a young age with fewer symptoms 156 
and exacerbations [11], or patients with severe respiratory disease but a low rate of comorbidities and 157 
older patients with a high rate of comorbidities (e.g., cardiovascular diseases and diabetes) but lower 158 
airway limitation and less obesity [12,13].    159 
Two studies [14,15] reported similar phenotypes with respect to COPD severity. Peters et al [14] 160 
identified three phenotypes in which patients were characterized by moderate COPD and a low 161 
impact on overall health status, moderate COPD with a high impact on health status, or severe COPD 162 
with a moderate impact on health status. Similarly, the three phenotypes identified by Garcia-163 
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Aymerich et al [15] were characterized by moderate, severe, and systemic COPD; the latter 164 
phenotype also had a high rate of cardiovascular comorbidities.  165 
When four phenotypes were reported, they also differed in terms of the severity of symptoms. 166 
Specifically, Yoon et al [9] clustered patients both according to their COPD severity (ie, mild, 167 
moderate, severe) and by identifying the ACO phenotype. A related work [7] classified patients 168 
according to the severity of emphysema (i.e., minimal, moderate, severe). Moreover, two studies 169 
[12,13] emphasized the distinction of two key population groups: a younger group of patients with 170 
moderate to severe respiratory disease but few comorbidities, and an older group with mild to severe 171 
airflow limitations but a high rate of cardiovascular comorbidities. 172 
In those articles that identified five phenotypes, the reported features were more homogeneous than 173 
those identified in studies reporting fewer phenotypes. For instance, almost every study reported 174 
similar comorbidities, namely cardiovascular and metabolic diseases (e.g., diabetes), obesity, and 175 
ACO, as possible confounding factors. In Burgel et al [8], the derived phenotypes confirmed other 176 
existing findings [12,13], suggesting the identification of an older group of patients with a high rate of 177 
cardiovascular comorbidities and diabetes but with less severe respiratory impairments. Similarly, 178 
Chen et al [16] acknowledged a group of young patients with mild airflow obstructions, few symptoms, 179 
and infrequent severe exacerbations vis-à-vis older patients with more symptoms, frequent severe 180 
exacerbations, and a high mortality rate.         181 
Overall, the diversity of phenotypes and populations presented in the current literature should not be 182 
surprising. Indeed, as we explain in the following, this scenario is largely due to an overarching limited 183 
reliance on statistical support in validating COPD with clinically meaningful outputs. Confirming our 184 
argument, for instance, a large study [30] carried out across ten independent cohorts from different 185 
populations in North America and Europe clearly showed that when identical methods were 186 
implemented for 17,146 individuals with COPD using common COPD-related characteristics, the 187 
reproducibility of COPD phenotypes across studies was rather modest. 188 
Studies excluded from the systematic analysis  189 
Ninety-nine studies were excluded either because a) they were irrelevant to COPD phenotypes or 190 
machine learning methods under study or b) the reported COPD phenotypes were not validated 191 
against clinical meaningful outcomes (Table 3). 192 




Twenty one of those studies identified between two [31] and nine [32] phenotypes; however the 195 
number of phenotypes most frequently reported were either three [33, 34, 35, 36], four [37, 38, 39, 40, 196 
41, 42, 43, 44] or five [45, 46, 47, 48, 49, 50, 51]. The works were predominantly observational – 12 197 
were cross-sectional [31, 33, 36, 38, 39, 40, 41, 42, 47, 48, 49, 51], six prospective [34, 43, 44, 45, 198 
46, 50], two retrospective [32, 37] and one randomised placebo controlled clinical trial [35]. Reported 199 
samples were comprised between 75 [36] and 3,144 [32] patients. In these studies, there was a 200 
remarkable heterogeneity among the reported phenotypes. For instance, when three phenotypes 201 
were reported, patients were characterized as either being young with few symptoms and mild airway 202 
limitation, or older and highly symptomatic with severe airway limitation or as a combination of both 203 
[34]. Moreover, de Torres et al. [34] showed that these phenotypes remained stable in most of the 204 
patients over a two years follow-up period.   205 
In studies with four phenotypes patients were characterized by the severity of the disease, i.e., 206 
patients with mild to moderate disease, moderate to severe emphysema, mild to increased dyspnoea, 207 
low to high exacerbation risk or even an overlap of asthma and COPD [38, 39, 41].  In one of these 208 
studies, Bafadhel et al [43] classified patients into four biologic clusters: a) bacterial-predominant, b) 209 
viral-predominant, c) eosinophilic-predominant and d) patients with limited changes in their 210 
inflammatory profile. 211 
In clusters of five phenotypes patients were characterized not only by the severity of the disease [45, 212 
48] but also by the presence of comorbidities [46] as well the asthma and COPD overlap syndrome 213 
[47, 48, 49]. We also observed a reported distinction between female patients with high body mass 214 
index, asthma, COPD, and symptom scores but no inflammation, and male patients with asthma and 215 
COPD with high eosinophil counts and low use of oral corticosteroids [47]. Another salient difference 216 
was shown between younger-onset asthma patients with severe symptoms and elderly patients with 217 
high frequency of comorbidities and concomitant COPD [50].     218 
A list of all potential phenotypes along with their groupings is displayed in the Appendix. Although this 219 




Study design 222 
Generally speaking, the retrieved research based on observational studies [6-8] highlights the 223 
advantage of capturing large cohorts of patients with COPD as well as the opportunity to showcase 224 
“real-life” outputs from clinical practice. Moreover, and in contrast to controlled experiments such as 225 
clinical trials in which patients are selected homogeneously to satisfy certain inclusion and exclusion 226 
criteria, an observational study allows researchers to appreciate the patients’ heterogeneity, which is 227 
a defining feature of COPD. Hence, the analysis of and outputs from such studies advance 228 
knowledge with respect to sample representativeness, covering actual COPD populations from 229 
different geographical settings.  230 
On the other hand, the results coming from observational studies may lead to the emergence of 231 
unstable phenotypes, in turn making treatment decisions more complex. Similarly, because 232 
observational studies are generally carried out in university hospitals, tertiary care centres or 233 
rehabilitation settings, they tend to cover only severe COPD patients and may not be fully 234 
representative of the wider COPD population.      235 
Validation 236 
Across the reviewed studies, we acknowledge that the derived COPD phenotypes were often 237 
validated both internally (i.e., from the same population in terms of clinically meaningful outcomes 238 
such as exacerbations, mortality, and response to therapy) and externally on a different population 239 
(e.g., including the rapid lung function decline or the asthma-COPD overlap phenotype in the 240 
ECLIPSE cohort). This procedure offers strong reliability as it provides evidence for the 241 
generalizability and robustness of the results. 242 
Data reduction and clustering 243 
Most of all, from our analysis of the literature, we can appreciate the recurrent use of statistical 244 
techniques aiming to reduce the size of the data and group patients with similar characteristics into 245 
distinct clusters. These approaches have the immediate advantage of utilizing all available 246 
information, yet in practice they “operationalize” phenotypes as if they were mathematical constructs 247 
and as a result they may not always be closely relevant to the medical condition.   248 
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As such, issues such as the handling of missing data or the choice of variables feeding the analysis 249 
become paramount features to ensure the consistency of phenotype identification in progressing with 250 
COPD research.  For instance, while the analysis of common features already offers a moderate 251 
concordance in determining COPD phenotypes [30], their robustness and reproducibility using an 252 
extended or diverse list of variables remains to be determined.  253 
We argue that one of the first steps needed to overcome the issue of ensuring the reproducibility and 254 
alignment of COPD phenotypes is situated, at least to some extent, in the variety of statistical 255 
methods used to derive them (Table 4). 256 
[Table 4 about here] 257 
Most of the reviewed literature used data reduction methods to select the variables to include in the 258 
cluster analysis [6-8,10-13,16]. These methods vary from Principal Components Analysis (PCA) [52] 259 
to Multiple Correspondence Analysis (MCA) [53] – a method similar to PCA yet using categorical data 260 
– and factor analysis. PCA, MCA, and factor analysis [54, 55] share the characteristic that they 261 
reduce data dimensionality to identify a small number of clinically relevant variables able to explain 262 
most of the variations occurring in COPD patients’ data. Whilst these approaches are beneficial to 263 
summarize data with a few variables without losing information, the interpretation of the derived 264 
variables within a clinical context is rarely straightforward due to their intimate mathematical nature. 265 
Other studies [9,14,15,17,19]
 
selected variables on either data availability and/or clinical expertise, 266 
i.e., by including a priori available variables deemed to be relevant to COPD alone. For instance, 267 
Chubachi et al [17] used only comorbidity data, while others used either a combination of lung 268 
function and demographic data (i.e., age, BMI, smoking status) [9,12,14,16,18] or a combination of 269 
lung function, demographic, comorbidity, and biomarker data [6,8,10,19]. Thus far, only a few articles 270 
combined all the above information with imaging and/or genetic data [7,11,13,15]. The variability in 271 
the choice of variables can thus lead to the unpredictability of the characteristics of the derived 272 
phenotypes. 273 
Noticeably, seven works used hierarchical analysis [8,10,11-13,17,19], which is a method in which 274 
each cluster is part of a larger cluster and they are all connected to each other like a tree (or 275 
dendrogram), whereby the number of clusters is determined by visual inspection [56]. Four studies 276 
[7,9,15,18] used k-means clustering, a method that splits the data into mutually exclusive clusters and 277 
in which the number of clusters needs to be specified in advance. Finally, two studies [6,16] used a 278 
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combination of hierarchical and k-means clustering, and one [14] used a combination of hierarchical 279 
and discriminant analysis, a technique that discriminates the categories of a dependent variable (e.g., 280 
symptoms) and evaluates the accuracy of this classification.  281 
 Missing values 282 
We note that regardless of the method used, an important aspect of these cluster analysis 283 
approaches is the handling of missing values. Indeed, most of the reviewed studies failed to address 284 
this issue. Research tended to use non-missing data to form COPD clusters without considering 285 
which phenotypes might have been formed if patients with missing data had been included in the 286 
analysis or if only a portion of them had been excluded. Only two studies [6,15] considered alternative 287 
methods for assessing the impact of excluding patients on the formation of COPD phenotypes. 288 
Pikoula et al [6] performed a sensitivity analysis by excluding all patients with a diagnostic code for 289 
asthma and identified four clusters. Notably, the atopic cluster did not present a strong enough 290 
discriminant ability to form a separate cluster. Thus, atopic patients were categorized as belonging to 291 
either the anxiety/depression or the not-comorbid phenotype. Garcia-Aymerich [15] instead 292 
considered the use of multiple imputation when implementing the cluster analysis [57], allowing 293 
simulated values to replace the missing ones and thereby enabling the use of data from all patients. 294 
 295 
Discussion 296 
There are several implications of clinical and medical relevance in using machine learning methods to 297 
extract data from different sources, such as radiology, imaging or genetics, to identify clinically 298 
relevant COPD phenotypes. In sum, these  include a better understanding of the natural history of the 299 
disease, the opportunity to more accurately identify high risk patient profiles, the prospect of early 300 
diagnosis and target treatments specific to certain phenotypes - along with the limitation of potentially 301 
adverse effects of unnecessary treatments, and the ability to make better and more precise 302 
predictions of treatment outcomes, thereby improving the prognosis of the disease and optimizing the 303 
use of health care resources.    304 
Building on the evidence emerging from this review, we can identify several recommendations for 305 
future research using cluster analysis to identify COPD phenotypes; these are summarized in Table 5. 306 
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These strategies include the use of large samples to make clinically meaningful associations and the 307 
handling of missing data to assess the robustness of the results. 308 
[Table 5 about here] 309 
Moving forward, in keeping with Bourbeau et al. [58], we suggest that regardless of the clustering 310 
method chosen, COPD-derived phenotypes should be validated both internally and externally. This 311 
aspect is central because clustering methods are data-driven techniques, thus the derived clusters 312 
might be subject to spurious groupings.  313 
As such, best practices in deriving COPD phenotypes include the utilization of prospective 314 
longitudinal data, which allows the assessment of variability and stability of features over time, as well 315 
as the use of cohorts from different settings to obtain the full spectrum of COPD phenotypes. The 316 
former recommendation implies carrying out large observational longitudinal cohort studies with at 317 
least a 3-year follow-up, as currently seen in the CALIBER [6] and ECLIPSE [24] studies. The latter 318 
proposal suggests using cohorts from different populations and settings to fully capture the 319 
heterogeneity of COPD. In this respect, we also envision the benefit of analysing cohorts including 320 
genetic information, such as COPDGene [7] or the UK Biobank database [59]. The immediate 321 
advantages of using such databases will be the opportunity to analytically and jointly assess patients’ 322 
clinical characteristics (eg, lung functionality), comorbidities, and biomarker data to strengthen the 323 
robustness of the COPD phenotypes as well as to better understand the underlying biological 324 
mechanisms of the condition. 325 
Ensuring clarity in the choice of variables used for identifying COPD phenotypes is another crucial 326 
recommendation for research using cluster analysis. This selection should always be evidence-based 327 
through experts’ opinions and/or published works to avoid choosing variables that might not be 328 
clinically relevant [58]. At the same time, we recognize that this approach may lead to previously 329 
unidentified patient characteristics being overlooked. Thus, we suggest that a reasonable compromise 330 
moving forward would be to use available evidence alongside clustering analysis. As such, the 331 
combination of hierarchical, k-means clustering, and clinical judgment appears to be the most suitable 332 





This article reviewed research published in the last decade on COPD phenotypes identified using 336 
cluster analysis and validated with clinically meaningful outcomes. To the best of our knowledge, this 337 
is one of the first works addressing such a systematization of the COPD literature. Moreover, it puts 338 
forward key recommendations to improve the study design, variables selection, external validation, 339 
and handling of missing data of prospective studies. 340 
Finally, we believe that future research should be tasked with further investigating COPD 341 
phenotype(s) whose characteristics have not yet been fully explored. For instance, the “fast decliner” 342 
phenotype [10,26,27], characterized by young patients with COPD with a fast decline in their lung 343 
function, as well as the cardiovascular comorbidity [6,13,25] characterized by differences in age, sex 344 
and high rates of hospital admission for AECOPD represent promising issues which are still largely 345 
unaddressed. Whichever the phenotype, we are hopeful that the insights presented here will soon 346 
enable research to better characterize additional patient determinants of COPD phenotypes and 347 
explore their association with responses to therapy while possibly developing more targeted 348 
treatments. 349 
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Table 1. 2019 GOLD classification of COPD phenotypes 
 Symptoms 
Moderate/severe exacerbation history mMRC 0-1 and CAT<10 mMRC≥2 and CAT≥10 
≥2 or ≥1 leading to hospital admission C D 
0 or 1 not leading to hospital admission A B 
mMRC, modified Medical Research Council dyspnea questionnaire; CAT, COPD assessment test 
 
Table 2. Summary of studies using clustering analysis to identify COPD phenotypes used in the systematic analysis 
 
First author 
and year of 
publication 




cluster analysis  









used for validation 
Yoon et al. 
(2019) [9] 






longitudinal cohort  
Patients with COPD 







2. Mild COPD 
3. Moderate COPD 
4. Severe COPD 
Acute exacerbation 





longitudinal cohort  
Patients who a) were 
35 years or older, b) 
had been registered 
for at least one year 
in primary care 
practice, c) had at 
least one diagnostic 
code of COPD  
1. Anxiety/depression 







5. Low prevalence of 
comorbidities 
Rate of severe or 





Kim et al. 
(2018) [10] 






Patients of Asian 
ethnicity, over 40 
years old with 
FEV1/FVC < 0.7 
assessed at 
pulmonary clinics 
1. Worse lung function 
but fewer symptoms 
2. Worse lung function 
with more symptoms 
and most frequent 
exacerbations, 
Exacerbations and 




and year of 
publication 




cluster analysis  













cohort   
faster FEV1 decline 
and greatest SGRQ 
decline 
3. Mild severity but 
higher BMI 
Kim et al. 
(2017) [11] 






Patients over 40 
years old with 
FEV1/FVC < 0.7 
living near cement 
plants who were 
evaluated at 
enrolment and at a 1-
year follow-up at 
university hospitals 














3. More female 
patients, additional 








quality of life 








Patients with stable 
COPD assessed at 
university hospitals 
1. Older patients with 
high rates of 
cardiovascular 
comorbidities and 







and year of 
publication 




cluster analysis  













b) the CPHG2 
prospective 
observational 






cohort (the 3CIA3 




2. Moderate to severe 
respiratory disease 
and low rate of 
comorbidities 
3. Older patients with 
high prevalence of 
comorbidities and 
obesity 
4. Very severe 
respiratory disease 




5. Mild respiratory 
disease and low 
rates of 
comorbidities 
Peters et al. 
(2017) [14] 
619 Two interventional 
cohorts: a) 1-year 
follow-up 
treatment as 




program     
Two groups of 
patients: 160 out-
patients with COPD 
treated as usual 
(TAU) and 459 
patients with 
pulmonary 
rehabilitation (PR) at 
a university medical 
centre 
1. Moderate COPD, 
low impact on health 
status (adaptive 
phenotype) 
2. Severe COPD, 
moderate impact on 
health status 
(adaptive) 
3. Moderate COPD, 
high impact on 
health status (non-
adaptive) 
Response to treatment 




and year of 
publication 




cluster analysis  









used for validation 
Chubachi et al. 
(2016) [17] 







COPD patients with 
complete 
comorbidities data 
with a 2-year follow-
up assessed at Keio 
University and its 
affiliated hospitals 
1. Less comorbidity 
2. Malignancy 






5. Underweight and 
anaemic 
Health-related quality 
of life (e.g. SGRQ, 
CAT, SF-36) 
Fingleton et al. 
(2015) [19] 
389 A 3-phase cross-
sectional study; 





study to assess 
treatment 




breathlessness in the 
last 12 months who 
completed phase 2 
with no missing data  





4. Mild atopic asthma 
5. Mild intermittent  








longitudinal cohort  
Men with COPD 
diagnosed at 
university hospital 


















and year of 
publication 




cluster analysis  









used for validation 
moderate 
respiratory disease, 










5. Patients with severe 
airflow obstruction, 
many symptoms 
and frequent severe 
exacerbations and 
high mortality 
Castaldi et al. 
(2014) [7] 









Former and current 
smokers with or 
without COPD  
1. No/mild obstruction 
and minimal 
emphysema 
2. Mild upper zone 
emphysema 
predominant 
3. Airway disease 
predominant 






al. (2012) [18] 
65 An interventional 
prospective 
cohort  
Patients with COPD 
participating in a 
pulmonary 
rehabilitation (PR) 
program at a 
university medical 
centre  
1. Worse lung function, 
quadriceps force but 
better response to 
exercise training 
2. Better lung function 
and exercise 






and year of 
publication 




cluster analysis  









used for validation 
response to 
exercise training 
Burgel et al. 
(2010) [12] 






Patients with stable 
COPD assessed at 
17 pulmonary units in 
university hospitals 
1. Young patients with 
severe respiratory 
disease 
2. Older patients with 
mild airflow 
limitation and mild 
comorbidities 
3. Young patients with 
moderate to severe 
airflow limitation, 
few comorbidities 
4. Older patients with 
moderate to severe 
airflow limitation and 




Burgel et al. 
(2012) [13] 
















1. Young patients with 
severe respiratory 




2. Older patients with 
less severe airflow 
limitation, obese, 










and year of 
publication 




cluster analysis  









used for validation 




limited comorbidities  
 
Garcia-
Aymerich et al. 
(2011) [15] 




hospitalized due to 
COPD exacerbation 
in teaching hospitals 




3. Systemic COPD 






CALIBER: A database of electronic health records from three national sources; The Clinical Practice Research Datalink (CPRD), Hospital 
Episode Statistics (HES), and cause-specific mortality from the Office for National Statistics (ONS) 
2
CPHG: The French College of General Hospital Respiratory Physicians  
3
3CIA: COPD Cohorts Collaborative International Assessment  
4
NZRHS: New Zealand Respiratory Health Survey  
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Table 3. Summary of studies excluded from the systematic analysis 
First author and year of 
publication 
Type and purpose of study Main findings COPD phenotypes Reason for exclusion 
Pascoe et al. (2019) [60] 
A randomized parallel group 
clinical trial aimed to model the 
relationships between 
eosinophil counts, smoking 
and treatment response to 
inhaled corticosteroids (ICS), 
and their interactions, including 
outcomes other than 
exacerbations. 
Results showed that 
assessment of blood 
eosinophil count and 
smoking status has the 
potential to optimize ICS 
use in clinical practice in 
patients with COPD and a 
history of exacerbations. 
 
Not applicable 
Not relevant to 
machine learning 
methods under study 
Sivapalan et al. (2019) 
[61] 
A randomized controlled non-
inferiority trial aimed to 
determine whether an 
algorithm based on blood 
eosinophil counts could safely 
reduce systemic corticosteroid 
exposure in patients admitted 
to hospital with acute 
exacerbations of COPD 
Results showed that 
eosinophil-guided therapy 
was non-inferior compared 
with standard care for the 
number of days alive and 
out of hospital, and 





Not relevant to COPD 
phenotyping 
van Geffen et al. (2019) 
[62] 
A systematic review and meta-
analysis aimed to evaluate the 
effects of volume reduction in 
the treatment of severe 
emphysema 
Results showed that lung 
volume reduction in 
patients with severe 
emphysema on maximal 





Not relevant to COPD 
phenotyping 
Sun et al. (2019) [63] 
A cross-sectional study 
designed to detect proteins 
that were differentially 
abundant in COPD frequent 
exacerbators and assess 
whether those expression 
profiles are unique among 
COPD patients 
Bioinformatics analyses of 
proteome indicated that the 
immune network for IgA 
production and the 
phenylalanine metabolism 





Not relevant with the 
machine learning 
methods under study 
Pichl et al. (2019) [64] 
A retrospective observational 
study investigated the 
treatment effect of riociguat 
and analysed the effect of 
Data showed that riociguat 
may be beneficial for 
treatment of PH-COPD 
 
Not applicable 
Not relevant with the 
machine learning 
methods under study 
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riociguat treatment on 
pulmonary hypertension (PH) 
in single patients with PH-
COPD 
Pragman et al. (2019) 
[65] 
A case-control observational 
study aimed to determine key 
features that differentiate the 
oral and sputum microbiota of 
frequent exacerbators (FEs) 
from the microbiota of 
infrequent exacerbators (IEs) 
during periods of clinical 
stability 
Data showed that the 
frequent exacerbator 
phenotype is associated 
with decreased alpha 
diversity, beta-diversity 




Not relevant with 
machine learning 
methods under study 
Xavier et al. (2019) [33] 
An observational cross-
sectional study aiming to 
investigate COPD phenotypes 
according to their levels of 
physical activity and sedentary 
behaviour, as well as body 
composition and skeletal 
muscle strength 
Cluster analysis identified 
three distinct COPD 
phenotypes 
1) more physically 
active, less sedentary 
and had better body 
composition and lower 
ADO index, 2) older, 
less physically active, 
more sedentary having 
a higher dyspnoea and 
obstruction (ADO) index, 
3) worse HRQoL, 
clinical control and body 
composition, less 
physically active, more 
sedentary having a 
higher ADO index 
COPD phenotypes 
were not validated with 
clinical meaningful 
outcomes 
Incalzi et al. (2019) [45] 
The STORICO Italian 
observational study aiming to 
describe multi-dimensional 
COPD phenotypes  
Machine learning methods 
used to identify five COPD 
phenotypes 
1) Mild COPD: no night-
time symptoms and the 
best health status in 
terms of quality of life, 
quality of sleep, level of 
depression and anxiety, 
2) Mild emphysematous: 
prevalent dyspnea in the 
early-morning and 
daytime, 3) Severe 
bronchitic: nocturnal and 
diurnal cough and 
COPD phenotypes 





phlegm, 4) Severe 
emphysematous: 
nocturnal and diurnal 
dyspnea, 5) Severe 
mixed COPD: higher 
frequency of symptoms 
during 24h and worst 
quality of life, of sleep 
and highest levels of 
depression and anxiety. 
Lainez et al. (2019) [37] 
A retrospective study aiming to 
identify asthma and COPD 
overlap (ACO) phenotypes 
Cluster analysis identified 
four ACO phenotypes 
1) overweighed heavy 
smokers, with an early 
onset and a severe 
disease, 2) similar 
patients, with a late 
onset, 3) and 4) slighter 
smokers, presenting a 
moderate disease, with 
early and late onset 
respectively 
ACO phenotypes were 
not validated with 
clinical meaningful 
outcomes 
Kukol et al. (2019) [66] 
A cross-sectional study aiming 
to identify COPD phenotypes 
of elderly patients 
Cluster analysis identified 
different COPD 





were not validated with 
clinical meaningful 
outcomes 
Pragman et al. (2019) 
[67] 
A genetic study aiming to 
determine features that 
differentiate the oral, nasal, 
and sputum microbiome 
among subjects with stable 
COPD 
Data showed associations 
between anatomic site and 
bacterial biomass, 




Not relevant to COPD 
phenotyping 
Haghighi et al. (2019) 
[38] 
A multi-center cross-sectional 
study aiming to identify COPD 
phenotypes using Quantitative 
computed tomographic (QCT) 
imaging  
Imaging-based cluster 
analysis identified four 
possible COPD 
phenotypes 
1) asymptomatic and 
showed relatively 
normal airway structure 
and lung function except 
airway wall thickening 
and moderate 
emphysema, 2) obese 
females showed an 
increase of tissue 
fraction at inspiration, 
COPD phenotypes 






and the lowest 
progression rate of 
emphysema, 3) older 
males showed small 
airway narrowing and a 
decreased tissue 
fraction at expiration, 
both indicating air-
trapping, 4) lean males 
were likely to be severe 
COPD subjects showing 
the highest progression 
rate of emphysema 
Bak et al. (2019) [68] 
A retrospective observational 
study aimed to assess 
prognostic impact among 
identified clusters in patient 
with idiopathic pulmonary 
fibrosis (IPF) and evaluate the 
impact of fibrosis and 
emphysema on lung function 
Cluster analysis identified 
distinct phenotypes, which 




Not relevant to COPD 
phenotyping 
Karayama et al. (2019) 
[39] 
A cross-sectional study aimed 
to identify novel COPD 
phenotypes using radiologic 
data 
Cluster analysis identified 
four COPD phenotypes 
1) mild emphysema with 
severe airway changes, 
severe airflow limitation, 
and high exacerbation 
risk, 2) mild emphysema 
with moderate airway 
changes, mild airflow 
limitation, and mild 
dyspnea, 3) severe 
emphysema with 
moderate airway 
changes, severe airflow 
limitation, and increased 
dyspnea, 4) moderate 
emphysema with mild 
airway changes, mild 
airflow limitation, low 
exacerbation risk, and 
COPD phenotypes 






Kneppers et al (2019) 
[69] 
A prospective observational 
study aimed to assess skeletal 
muscle molecular responses to 
Pulmonary rehabilitation (PR) 
in COPD patients 
Cluster analysis identified 
patient groups with distinct 
skeletal muscle molecular 




were not validated with 
clinical meaningful 
outcomes 
de Torres et al. (2018) 
[34] 
A prosepctive observational 
study aimed to evaluate the 2-
year cluster variability in stable 
COPD patients. 
Data showed that after 2 
years of follow-up, most of 
the COPD patients 
maintained their cluster 
assignment 
1) younger age, mild 




clusters 1 and 3), 3) 
older age, severe airway 
limitation and highly 
symptomatic 
COPD phenotypes 
were not validated with 
clinical meaningful 
outcomes 
Gedebjerg et al. (2018) 
[70] 
A prospective observational 
study aimed to establish the 
predictive ability of the GOLD 
2017 classification, compared 
with earlier classifications, for 
all-cause and respiratory 
mortality 
Data showed that the new 
GOLD 2017 ABCD 
classification does not 
predict all-cause and 
respiratory mortality more 
accurately than the 
previous GOLD systems 
from 2007 and 2011 
 
Not applicable 
Not relevant to COPD 
phenotyping and to 
machine learning 
methods under study 
Merrill et al. (2018) [71] 
Data from two randomized 
clinical trials aimed to 
investigate the response to 
specific interventions 
according to heart failure (HF) 
phenotype  
Response to treatments 
such as exercise training 
and spironolactone varies 




Not relevant to COPD 
phenotyping  
El Boueiz (2018) [72] 
A prospective observational 
study aimed to improve the 
predicted ability in COPD 
progression 
Results showed that 
machine learning methods 
improved the prediction 




Not relevant to COPD 
phenotyping  
Fang et al. (2018) [73] 
A cross-sectional study aimed 
to estimate the COPD 
prevalence in China 
Data showed that the 
estimated overall 
prevalence of COPD in 




Not relevant to COPD 
phenotyping 
Koo et al. (2018) [74] A cross-sectional study aimed Data showed that small  Not relevant to COPD 
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to determine whether 
destruction of the terminal and 
transitional bronchioles occurs 
before, or in parallel with, 
emphysematous tissue 
destruction 
airways disease is a 
pathological feature in mild 
and moderate COPD 
Not applicable phenotyping 
Liang et al. (2018) [75] 
A simulation study aimed to 
develop a novel variable 
reduction method for joint 
analysis of multiple 
phenotypes in association 
studies 
Results showed that this 
novel method can be used 
in analyzing a whole-
genome genotyping data 
 
Not applicable 
Not relevant with the 
machine learning 
methods under study 
Raherison et al. (2018) 
[46] 
A prospective observational 
study aiming to determine the 
association between specific 
comorbidities and COPD 
severity. 
Cluster analysis identified 
five phenotypes of 
comorbidities 
1) included cardiac 
profile, 2) included less 
comorbidities, 3) 
included metabolic 
syndrome, apnea and 
anxiety-depression, 4) 




were not validated with 
clinical meaningful 
outcomes 
Kilk et al. (2018) [76] 
A pilot study aiming to 
characterize patients with 
COPD, based on the 
metabolomic profiling of 
peripheral blood and exhaled 
breath condensate (EBC) 
within the context of defined 
clinical and demographic 
variables. 
Cluster analysis did not 
reveal a clinical-
metabolomic stratification 
superior to the strata set by 




were not validated with 
clinical meaningful 
outcomes 
de Vries et al. (2018) [47] 
A multi-centre cross-sectional 
study to capture 
clinical/inflammatory 
phenotypes in patients with 
chronic airway disease using 
an electronic nose (eNose) in 
a training and validation set 
Cluster analysis identified 
five combined asthma and 
COPD phenotypes 
1) Asthma and COPD: 
predominantly females, 
high BMI, high symptom 
scores, low FeNO, no 
inflammation measured 
in blood, 2) Asthma and 
COPD: predominantly 
males, high circulating 
eosinophil counts, high 
FeNO, low use of oral 
COPD phenotypes 






Asthma and COPD: 
predominately non-
Caucasian, poor lung 
function, eosinophil 
blood counts of 
0.45±1.3×109 cells·L-1, 
lowest exacerbation rate 
in the past 3 months, no 
OCS use, low use of 
ICS, 4) Asthma and 
COPD: predominantly 
atopic, high circulating 
neutrophil blood counts, 
highest number of 
exacerbations per 
person in the past 3 
months, 5) fewer COPD 
patients, best 
postbronchodilator 
FEV1, relatively low 
exacerbation rate per 
person in the past 3 
months 
Le Rouzic et al. (2018) 
[77] 
A prospective observational 
study aimed to confirm the 
existence of the frequent 
exacerbator phenotype 
Data confirmed the 
existence of the frequent 
exacerbator and the 





were not validated with 
clinical meaningful 
outcomes 
Vazquez Guillamet et al. 
(2018) [32] 
A retrospective observational 
study aimed to identify COPD 
phenotypes from electronic 
medical records 
Cluster analysis identified 
nine COPD phenotypes 
1) depression–chronic 
obstructive pulmonary 















pulmonary disease, 5) 
advanced malignancy–
chronic obstructive 
















Hall et al. (2018) [78] 
An observational prospective 
study aimed to determine the 
extent to which multimorbidity 
is associated with long-term 
survival following acute 
myocardial infarction (AMI) 
Three multimorbidity 
phenotype clusters that 
were significantly 
associated with loss in life 
expectancy were identified 
and should be a 
concomitant treatment 




Not relevant to COPD 
phenotyping 
Das et al. (2018) [79] 
A review of machine learning 
methods in the diagnosis of 
COPD 
The application of artificial 
intelligence has produced 
promising results in the 
diagnosis of COPD 
 
Not applicable Not relevant to COPD 
phenotyping 
Merchant et al. (2018) [80] 
A prospective observational 
study aimed to assess the 
impact of digital intervention on 
asthma health resource 
utilization 
Results showed that digital 
health interventions can be 
incorporated into routine 
clinical practice, and their 










 Radin et al. (2017) [31] 
A cross-sectional study aimed 
to identify novel COPD 
phenotypes based on 
computed tomography (CT) 
densitometry 
Cluster analysis showed 
the CT densitometry 
identified two distinct 
phenotypes of COPD   
Cluster 1 has subjects 
with decreased FEV1, 
FEV/FVC, FEF at 25-
75% of FVC and BMI 
and increased residual 
volume and total lung 
capacity compared to 
cluster 2 
The derived 
phenotypes were not 
validated with clinical 
meaningful outcomes 
Christenson et al. (2017) 
[81] 
A randomized placebo-
controlled clinical trial aimed to 
explore airway epithelial mucin 
gene expression heterogeneity 
in COPD  
Cluster analysis identified 
that 2 COPD subgroups in 
which either MUC5AC or 
MUC5B gene expression is 
elevated. These subgroups 
are associated with 
specific inflammatory 
patterns 
2 COPD subgroups in 
which either MUC5AC 
or MUC5B gene 
expression is elevated 
The derived 
phenotypes were not 
validated with clinical 
meaningful outcomes 
Kästle et al (2017) [82] 
A genetic study aimed to 
identify specific miRNAs 
implicated in controlling Th17 
differentiation 
Results showed evidence 
of miRNAs involvement in 
controlling the 
differentiation and function 
of T helper cells, offering 





Not relevant with the 
machine learning 
methods under study 
Fouda et al (2017) [83] 
A prospective observational 
study on the association 
between osteoporosis and 
emphysema in a model that 
includes these potentially 
confounding factors 
Results showed that 
emphysematous 
phenotype is not a risk 
factor for osteoporosis 
independently of BMI, 
FEV1, and PaO2. 
 
Not applicable 
Not relevant with the 
machine learning 
methods under study 
Chalmers JD (2017) [84] 
A review on bronchiectasis 
characterization 
Key developments in the 
bronchiectasis field include 
the establishment of 
international disease 
registries and 
characterization of disease 
phenotypes using cluster 




Not relevant to COPD 
phenotyping and 
machine learning 
methods under study 
Fingleton et al. (2017) A cross-sectional Cluster analysis identified 1) severe late-onset COPD phenotypes 
2 
 
[48] observational study aiming to 
compare the phenotypes of 
airways disease in two 
separate populations (China 
and New Zealand) 
five COPD phenotypes that 
were similar in both 
populations 
asthma/COPD overlap 
group, 2) moderately 
severe early-onset 
asthma/COPD overlap 
group, 3) moderate to 
severe asthma group 
with type 2 predominant 
disease, 4 and 5) 
minimal airflow 
obstruction, 
differentiated by age of 
onset. 
were not validated with 
clinical meaningful 
outcomes 
Zarei et al. (2017) [35] 
A randomized placebo-
controlled trial aimed to identify 
COPD phenotypes using 
proteomic data 
Cluster analysis identified 
three COPD phenotypes 
The third cluster had 
less emphysema and 
worse disease-related 
quality of life, despite 
similar levels of lung 
function impairment than 
the other two groups 
COPD phenotypes 
were not validated with 
clinical meaningful 
outcomes 
Hirai et al. (2017) [85] 
A prospective observational 
study aimed to clarify the 
discriminant factors for 
assigning the asthma-COPD 
overlap phenotype 
Data showed that the 
asthma-COPD overlap 
phenotype was 
characterized by peripheral 
blood eosinophilia and 
higher levels of IgE despite 
the Th2-low endotype. 
 
peripheral blood 
eosinophilia and higher 
levels of IgE despite the 
Th2-low endotype 
COPD phenotypes 
were not validated with 
clinical meaningful 
outcomes 
Lee et al. (2017) [49] 
A national survey aimed to 
identify subtypes in patients 
with mild-to-moderate airflow 
limitation and to appreciate 
their clinical and 
socioeconomic implications 
Cluster analysis identified 
five phenotypes with 
different level of health 
care utilization  
1) near-normal: oldest 
mean age, highest 
FEV1, 2) asthmatic: 
youngest, lowest 
prescription rate,despite 
the highest proportion of 
self-reported wheezing, 
3) chronic obstructive 
pulmonary disease 
(COPD): male 
predominant and all 
current or ex-smokers, 
high prescription rate of 
respiratory medicine, 4) 
COPD phenotypes 






prescription rate of 
respiratory medicine, 5) 
COPD-overlap: male 
predominant and all 
current or ex-smokers, 
high prescription rate of 
respiratory medicine. 
 
Haldar et al (2017) [86] 
A genetic study aimed to 
assess whether the balance 
between the two dominant 
bacterial groups 
(Gammaproteobacteria (G) 
and Firmicutes (F)) in COPD 
sputum samples might reveal 
a subgroup with a bacterial 
community structure change at 
exacerbation that was restored 
to baseline on recovery and 
potentially reflects effective 
antibiotic treatment. 
Results showed that the 
G:F ratio at exacerbation 
can be determined on a 
timescale compatible with 




Not relevant to COPD 
phenotyping 
Çolak et al. (2017) [87] 
A prospective observational 
study aimed to investigate the 
prognosis of individuals with 
asymptomatic and 
symptomatic, undiagnosed 
COPD in the general 
population in Denmark. 
Individuals with 
undiagnosed, symptomatic 
COPD had an increased 
risk of exacerbations, 
pneumonia, and death. 
Individuals with 
undiagnosed, 
asymptomatic COPD had 





Not relevant to 
machine learning 
methods under study 
Maddocks et al. (2016) 
[88] 
A randomized placebo-
controlled trial aimed to assess 
the effectiveness of 
neuromuscular electrical 
stimulation (NMES) as a 
home-based exercise therapy 
Data showed that NMES 
improves functional 
exercise capacity in 
patients with severe COPD 
by enhancing quadriceps 
muscle mass and function. 
 
Not applicable 
Not relevant to COPD 
phenotyping 
Lange et al. (2016) [89] A prospective observational Data showed that the  Not relevant to COPD 
2 
 
study aimed to investigate the 
long-term prognosis of 
individuals with different types 
of chronic airway disease and 
asthma-COPD overlap 
prognosis of individuals 
with asthma-COPD overlap 
is poor and seems to be 
affected by the age of 
recognition of asthma, 
being worst in those with 
late asthma onset (after 40 
years of age) 
Not applicable phenotyping 
Papi et al (2016) [24]  
A prospective observational 
study aimed to define COPD 
phenotypes and identify 
biomarkers and/or genetic 
parameters that help to predict 
disease progression 
The study highlights some 
of the progress in 
phenotyping the 
heterogeneity of the 
disease 
that have been made 
thanks to the analyses of 
this longitudinal study 
 
Not applicable 
Not relevant to 
machine learning 
methods under study 
Ning et al. (2016) [40] 
A cross-sectional analysis 
aimed to identify distinct 
COPD phenotypes  
Cluster analysis identified 
four phenotypes 
1) COPD patients with 
moderate to severe 
airflow limitation, 2) 
asthma and COPD 
patients with heavy 
smoking, airflow 
limitation and increased 
airways reversibility, 3)  
patients having less 
smoking and normal 
pulmonary function with 
wheezing but no chronic 
cough, 4) chronic 
bronchitis patients with 
normal pulmonary 
function and chronic 
cough 
COPD phenotypes 
were not validated with 
clinical meaningful 
outcomes 
Rootmensen et al. (2016) 
[41] 
A cross-sectional study aimed 
to identify COPD phenotypes 
in an outpatient population 
Cluster analysis identified 
four COPD phenotypes 
1) patients with a history 
of extensive cigarette 
smoking, airway 
obstruction without signs 
of emphysema, 2) 
patients with features of 
the emphysematous 
COPD phenotypes 





type of COPD, 3) 
patients with 
characteristics of allergic 
asthma, 4) patients with 
features suggesting an 
overlap syndrome of 
atopic asthma and 
COPD 
Sekiya et al. (2016) [50] 
A prospective observational 
study aimed to examine the 
clinical characteristics and 
heterogeneity of patients with 
severe or life-threatening 
asthma exacerbation.  
Cluster analysis identified 
five distinct asthma 
phenotypes 
1) younger-onset 
asthma with severe 
symptoms at baseline, 
including limitation of 
activities, a higher 
frequency of treatment 
with oral corticosteroids 
and short-acting beta-
agonists, and a higher 
frequency of asthma 
hospitalizations in the 
past year, 2) 
predominantly 
composed of elderly 
females, with the 




polyposis, and a long 
disease duration, 3) 
allergic asthma without 
inhaled corticosteroid 
use at baseline. Patients 
in this cluster had a 
higher frequency of 
atopy, including allergic 
rhinitis and furred pet 
hypersensitivity, and a 
better prognosis during 
hospitalization 
compared with the other 
Not relevant to COPD 
phenotyping; not 




clusters, 4) elderly 
males with concomitant 
chronic obstructive 
pulmonary disease 
(COPD), 5) very mild 
symptoms at baseline 
according to the patient 
questionnaires, 41% 
had previously been 
hospitalized for asthma 
Sato et al. (2016) [90]  
A retrospective study aiming to 
identify phenotypes of patients 
with idiopathic interstitial 
pneumonia (IIP) with 
pulmonary emphysema (PE) 
Cluster analysis identified 
three phenotypes; 
idiopathic pulmonary 
fibrosis (IPF) with PE is a 




Not relevant to COPD 
phenotyping 
Morélot-Panzini et al. 
(2016) [91] 
An observational prospective 
study testing the 
Multidimensional Dyspnea 
Profile (MDP) in COPD 
patients 
The MDP can identify an 
affective/emotional 
dimension of dyspnea and 
contribute to phenotypic 




were not validated with 
clinical meaningful 
outcomes 
Roche et al. (2016) [92] 
A cross-sectional study 
investigating the genetic 
variability of COPD and 
obstructive sleep apnea 
patients 
The study identified 
genetic variants mapping 




Not relevant to COPD 
phenotyping 
Martínez-García et al. 
(2016) [93] 
An observational cohort study 
aimed to identify phenotypes 
for non-cystic fibrosis 
bronchiectasis  
Using cluster analysis, it 
was possible to identify 
distinct phenotypes 
 
Not applicable Not relevant to COPD 
phenotyping 
Batista-Navarro et al. 
(2016) [94] 
A cross-sectional qualitative 
study that compared a manual 
performing task of COPD 
phenotype curation to that of a 
text-mining algorithm  
Text-mining algorithms 
were more efficient in 
facilitating the curation of 
COPD phenotypes  
 
Not applicable 
Not relevant to 
methods under study; 
not validated with 
clinical outcomes 
Labuzzetta et al. (2016) 
[95] 
A genetic cross-sectional study 
that uses machine learning 
methods to predict COPD 
phenotypes 
Machine learning methods 
showed that isoform 
expression data have high 
accuracy in predicting 
phenotypes 
 
Not applicable Predicted phenotypes 




Kaluarachchi et al. (2016) 
[96] 
A case-control study aimed to 
determine perturbed 
biochemical functions 
associated with tobacco 
smoking 
Results showed that 
combining multiplatform 
metabolic phenotyping with 
knowledge-based mapping 
gives mechanistic insights 
into disease development 
 
Not applicable 
Not relevant to COPD 
phenotyping 
Obeidat et al. (2015) [97] 
A genome-wide association 
study aimed to investigate 
molecular mechanisms 
underlying variations in lung 
function 
The system genetics 
approach identified lung 
tissue genes driving the 
variation in lung function 
and susceptibility to COPD 
 
Not applicable 
Not relevant to COPD 
phenotyping 
Kim et al. (2015) [98] 
A cross-sectional study aimed 
to identify novel lung disease 
phenotypes using multi-omics 
data   
Cluster analysis identified 
subclusters with distinct 




Not relevant to COPD 
phenotyping; not 
validated with clinical 
meaningful outcomes 
Hübenthal et al. (2015) 
[99] 
A case-control study that used 
genetic profiling and machine 
learning methods to accurately 
predict inflammatory diseases 
The proposed miRNA 
signature is of relevance 





Not relevant to COPD 
phenotyping 
Lee et al. (2014) [100] 
An observational genetic study 
aimed to investigate the 
clinical and genetic 
heterogeneity in subjects with 
mild airflow limitation in 
spirometry grade 1 defined by 
the Global Initiative for COPD 
Results showed that GOLD 
1 subjects show 
substantial clinical 
heterogeneity, which is at 





phenotypes were not 
validated with clinical 
meaningful outcomes 
Uzun et al. (2014) [101] 
A randomized placebo-
controlled trial aimed to 
investigate whether patients 
with COPD who had received 
treatment for three or more 
exacerbations in the previous 
year would have a decrease in 
exacerbation rate when 
maintenance treatment with 
azithromycin was added to 
standard care 
Data showed that 
maintenance treatment 
with azithromycin 
significantly decreased the 
exacerbation rate 
compared with placebo 
 
Not applicable 
Not relevant to COPD 
phenotyping 
Brightling et al. (2014) 
[102] 
A randomized placebo-
controlled trial aimed to 
Results showed that 
compared with placebo, 
 
Not applicable 





benralizumab reduces acute 
exacerbations of COPD in 
patients with eosinophilia and 
COPD 
benralizumab did not 
reduce the rate of acute 
exacerbations of COPD 
Kon et al. (2014) [103] 
Three prospective 
observational studies aimed to 
assess the he minimum 
clinically important difference 
(MCID) for the COPD 
Assessment Test (CAT) in 
patients with COPD 
The most reliable estimate 
of the minimum important 




Not relevant to COPD 
phenotyping 
Köhnlein et al. (2014) 
[104] 
A prospective randomized 
controlled clinical trial aimed to 
investigate the effect of long-
term non-invasive positive 
pressure ventilation (NPPV), 
targeted to markedly reduce 
hypercapnia, on survival in 
patients with advanced, stable 
hypercapnic COPD 
Results showed that the 
addition of long-term NPPV 
to standard treatment 
improves survival of 
patients with hypercapnic, 
stable COPD when NPPV 
is targeted to greatly 
reduce hypercapnia.  
 
Not applicable 
Not relevant to COPD 
phenotyping 
Jones et al. (2014) [105] 
A retrospective study aimed to 
investigate patterns of health-
care use and comorbidities 
present in patients in the 
period before diagnosis of 
chronic obstructive pulmonary 
disease (COPD) 
Data showed that 
opportunities to diagnose 
COPD at an earlier stage 
are being missed, and 
could be improved by 
case-finding in patients 
with lower respiratory tract 




Not relevant to COPD 
phenotyping 
Zheng et al. (2014) [106] 
A randomized placebo-
controlled trial aimed to assess 
whether N-acetylcysteine 
could reduce the rate of 
exacerbations in patients with 
COPD 
Data showed that in 
Chinese patients with 
moderate-to-severe 
COPD, long-term use of N-
acetylcysteine 600 mg 
twice daily can prevent 
exacerbations, especially 




Not relevant to COPD 
phenotyping 
Corhay et al. (2014) A cross-sectional study aimed Cluster analysis can help  COPD phenotypes 
2 
 
[107] to summarize the current data 
available about the 
phenotypes of this disease  
to identify more precise 
definition of COPD 
phenotypes 
Not applicable were not validated with 
clinical meaningful 
outcomes 
Moore et al. (2014) [108] 
A cross-sectional study aiming 
to understand the interactions 
between inflammation and 
clinical asthma subphenotypes 
Cluster analysis identified 
four phenotypes 
associated with asthma 
severity 
 
Not applicable Not relevant to COPD 
phenotyping 
Qiao et al. (2014) [109] 
A simulation study 
investigating the association 
between genetic loci and 
complex phenotypes 
Cluster analysis can be 
useful in genome 
sequencing studies for 
pairing genomic regions 
with complex phenotypes 
 
Not applicable 
Not relevant to COPD 
phenotyping 
DiSantostefano et al. 
(2014) [110] 
Baseline data of two clinical 
trials were used to identify risk 
groups for pneumonia 
Cluster analysis can 
identified distinct patient 
groups at risk of 
pneumonia 
 
Not applicable Not relevant to COPD 
phenotyping 
Vogelmeier et al. (2013) 
[111] 
A randomized parallel group 
trial aimed to compare the 
efficacy, safety, and tolerability 
of QVA149 versus salmeterol-
fluticasone (SFC) over 26 
weeks in patients with 
moderate-to-severe COPD 
Results suggested the 
potential of dual 
bronchodilation as a 





Not relevant to COPD 
phenotyping 
Franciosi et al. (2013) 
[112] 
Four clinical trials aimed to 
assess the efficacy and safety 
of a novel inhaled dual 
phosphodiesterase 3 (PDE3) 
and PDE4 inhibitor, RPL554 
for its ability to act as a 
bronchodilator and anti-
inflammatory drug 
Data showed that inhaled 







Not relevant to COPD 
phenotyping 
Decramer et al. (2013) 
[113] 
A randomized parallel group 
study aimed to compare the 
efficacy and safety of 
indacaterol and tiotropium in 
patients with COPD 
Data showed that 
Indacaterol and tiotropium 
provided clinically relevant 
improvements in lung 




Not relevant to COPD 
phenotyping 
Dransfield et al. (2013) 
[114] 
Two parallel group randomized 
controlled trials aimed to 
investigate whether fluticasone 
Results showed that 
addition of fluticasone 
furoate to vilanterol was 
 
Not applicable 




furoate and vilanterol would 
prevent more exacerbations 
than would vilanterol alone 
associated with a 
decreased rate of 
moderate and severe 
exacerbations of COPD in 
patients with a history of 
exacerbation, but was also 
associated with an 
increased pneumonia risk 
Wedzicha et al. (2013) 
[115] 
A randomized parallel-group 
study aimed to evaluate the 
effect of dual, longacting 
inhaled bronchodilator 
treatment on exacerbations in 
patients with severe and very 
severe chronic obstructive 
pulmonary disease (COPD) 
Results suggested 
potential of dual 
bronchodilation as a 
treatment option for 
patients with severe and 
very severe COPD. 
 
Not applicable 
Not relevant to COPD 
phenotyping 
Rabe et al. (2013) [116] 
A randomized parallel-group 
study aimed to establish 
whether ADRB2 
polymorphisms differentially 
affected COPD exacerbation 
outcomes in response to 
tiotropium versus salmeterol. 
Data showed limited 
evidence for the use of 
ADRB2 polymorphisms for 




Not relevant to COPD 
phenotyping 
Siedlinski et al. (2013) 
[117] 
A case-control study aimed to 
estimate direct and indirect 
effects of genetic loci on 
COPD development using 
mediation analysis 
This study confirms the 
existence of direct effects 
of the AGPHD1/CHRNA3, 
IREB2, FAM13A and HHIP 
loci on COPD 
development. 
 
Not applicable Not relevant to COPD 
phenotyping and 
machine learning 
methods under study 
Gouzi et al. (2013) [118] 
A cross-sectional study aimed 
to test whether muscle fiber 
atrophy and increased 
oxidative stress constitute the 
attributes of validated COPD 
phenotypes 
Data showed that 
demonstrates that the 
muscle heterogeneity is 
the translation of different 
phenotypes of the disease. 
 
Not applicable COPD phenotypes 
were not validated with 
clinical meaningful 
outcomes 
Fens et al. (2013) [42] 
A cross-sectional study aimed 
to identify subphenotypes of 
COPD in a community-based 
population of heavy (ex-) 
smokers 
Cluster analysis identified 
four COPD phenotypes 
1) mild COPD, limited 
symptoms and good 
quality of life, 2) low lung 
function, combined 
emphysema and chronic 
COPD phenotypes 





bronchitis and a distinct 
breath molecular profile, 
3) emphysema 
predominant COPD with 
preserved lung function, 
4) highly symptomatic 
COPD with mildly 
impaired lung function. 
Shaykhiev et al. (2013) 
[119] 
A genetic study investigating 
the association between 
CXCL14 gene, cancer and 
COPD  
Data showed that smoking-
induced gene expression is 
a potential link between 
smoking-associated airway 
epithelial injury, COPD, 
and lung cancer.  
 
Not applicable 
Not relevant to COPD 
phenotyping 
Carolan et al. (2013) 
[120] 
A review that discusses 
advances in describing 
phenotypic variability in 
asthma and COPD 
The authors suggest that 
better understanding of the 
heterogeneity of the 
disease through 
phenotyping will improve 
care and reduce potential 




Not relevant to 
methods under 
study.i.e. a review - not 
original research study 
 Basagaña et al. (2013) 
[39] 
In this article the authors 
developed a framework of 
applying imputation to missing 
values of a cluster analysis 
The proposed framework 
deals with uncertainty in 
definine the number of 
clusters, the variable 
selection and allocation of 
patients to clusters 
 
Not applicable 
Not relevant to the 
studies under review 
Toraldo et al. (2012) 
[121] 
A review article that discusses 
and refines the concept of 
desaturator phenotypes in 
COPD with pulmonary 
hypertension (PH) 
Cluster analysis can 
identify a pattern of 
phenotypic markers that 
could be used as a 
framework for future 
diagnosis and research 
 
Not applicable Not relevant to COPD 
phenotyping and 
machine learning 
methods under study 
Travers et al. (2012) 
[122] 
In a letter to the editors the 
authors discuss the possibility 
of re-examining the 
classification of airways 
disease to identify disease 
subgroups that may respond to 
The authors conclude that 
classification analysis can 
be used to derive 
allocation rules that allow 
disease groups identified 
through cluster analysis to 
 
Not applicable 
Not relevant to 
machine learning 
methods under study 
2 
 
treatments in different ways. be prospectively identified 
in the real world. This will 
enable trials to test 
interventions in putative 
phenotypes, a necessary 
step towards personalised 
medicine for airways 
disease. 
Toraldo et al. (2011) 
[123] 
A cross-sectional study aimed 
to discuss and refine the 
concept of phenotyping 
desaturators in COPD and 
shows a possible pattern 
which could be used as a 
framework for future research. 
The study suggests that 
COPD phenotyping can 
facilitate our understanding 
and management of COPD 
 
Not applicable 
Not relevant to 
machine learning 
methods under study 
 Bafadhel et al. (2011) 
[36] 
A cross-sectional study aimed 
to study the application of CT 
imaging in the 
multidimensional approach to 
phenotyping patients with 
COPD 
Cluster analysis identified 
three clusters, two of which 
were emphysema 
predominant and the third 










combination of EM and 
BE 
The derived 
phenotypes were not 
validated with clinical 
meaningful outcomes 
Bafadhel et al. (2011) 
[43] 
A prospective observational 
study aimed to investigate 
biomarker expression in COPD 
exacerbations to identify 
biologic clusters and determine 
biomarkers that recognize 
clinical COPD exacerbation 
phenotypes 
Cluster analysis identified 






predominant, 4) limited 
changes in the 
inflammatory profile 
COPD phenotypes 
were not validated with 
clinical meaningful 
outcomes 
Fingleton et al. (2011) 
[124] 
In a letter to the editors the 
authors discuss the tailoring of 
treatment regiments to patients 
with different COPD 
phenotypes 
The author acknowledge 
the challenge to determine 
distinct phenotypes and 
suggest that if these 
phenotypes are validated 
with response to treatment 
then can be potentially 
used to target treatments 
 
Not applicable 
Not relevant to 
methods under study, 
i.e. a review - not 
original research study 
2 
 
specifically to patients 
Shirtcliffe et al. (2011) 
[125] 
This review aimed to a better 
understanding of the distinct 
disorders of airways disease 
with the potential to inform on 
underlying mechanisms, risk 
factors, natural history, 
monitoring and treatment. 
The authors conclude that 
by further defining the 
distinct phenotypes that 
make up the syndromes of 
asthma and COPD could 
lead to treatments 
specifically targeted for 
defined phenotypic groups. 
 
Not applicable 
Not relevant to 
methods under study, 
i.e. a review - not 
original research study 
Sharma et al. (2010) 
[126] 
A study used data from two 
clinical trials aimed to identify 
subject clusters in one study 
and replicate the findings in 
the second study 
Cluster analysis identified 
three subjects clusters in 
one study that were 





phenotypes were not 
validated with clinical 
meaningful outcomes 
Jo et al. (2010) [127] 
A cross-sectional 
observational study aimed to 
classify the phenotypes in 
elderly subjects with 
obstructive lung disease (OLD) 
Cluster analysis identified 
three phenotypes in elderly 




phenotypes were not 
validated with clinical 
meaningful outcomes 
Cho et al. (2010) [44] 
An observational genetic study 
aimed to identify subtypes of 
severe emphysema 
Cluster analysis identified 
four phenotypes in a group 





responsive, with higher 
FEV1, 3) discordant, 
with a lower FEV1 
despite less severe 
emphysema and lower 
airway wall thickness, 4) 
airway predominant. 
The derived 
phenotypes were not 
validated with clinical 
meaningful outcomes 
Sobradillo et al. (2010) 
[128] 
In this article the authors 
review the knowledge in the 




Not relevant to the 
purpose of the review 
under study 
 Weatherall et al. (2010) 
[129] 
In this article the authors 
discuss the advantages and 
disadvantages of cluster 
analysis to characterize 
different types of airways 
disorders 
The author conclude that 
cluster analysis can help to 
better understanding the 
true patterns of airway 
disorders and could lead to 
different pharmacological 
treatments and other 
interventions directed at 
 
Not applicable 
Not relevant to 
machine learning 
methods under study 
2 
 
specific phenotypic group 
Paoletti et al. (2009) 
[130] 
A cross-sectional study aimed 
to assess the presence of 
hidden structures in data 
corresponding to the different 
COPD phenotypes observed in 
clinical practice 
Data showed that using 
cluster analysis can 
identify phenotypes for 
understanding the results 
of pharmacologic trials; 
clinician’s approach to 
patient treatment and 




phenotypes were not 
validated with clinical 
meaningful outcomes 
Weatherall et al. (2009) 
[51] 
A cross-sectional study aimed 
to explore clinical phenotypes 
in a community population with 
airways disease 
Cluster analysis identified 
five distinct phenotypes of 
airflow obstruction 
1) severe and markedly 
variable airflow 
obstruction with features 
of atopic asthma, 
chronic bronchitis and 
emphysema, 2) features 
of emphysema alone, 3) 
atopic asthma with 
eosinophilic airways 
inflammation, 4) mild 
airflow obstruction 
without other dominant 
phenotypic features, 5) 
chronic bronchitis in 
nonsmokers 
The derived 
phenotypes were not 
validated with clinical 
meaningful outcomes 
Pistolesi  et al. (2008) 
[131] 
A cross-sectional study aimed 
to ascertain whether COPD 
phenotypes reflecting different 
mechanisms of airflow 
limitation could be clinically 
identified 
Results showed that 
patients with COPD can be 
assigned a clinical 
phenotype reflecting the 
prevalent mechanism of 
airflow limitation 
 
Not applicable Not relevant to COPD 
phenotyping and 
machine learning 
methods under study 
Patel et al. (2008) [132] 
An observational study aiming 
to assess the association 
between airway wall thickening 
and emphysema at the 
severity of COPD  
Airway wall thickening and 
emphysema make 
independent contributions 
to airflow obstruction in 
COPD. 
 
Not applicable Not relevant with 
machine learning 
methods under study 
Kodavanti et al. (2006) 
[133] 
An animal study investigating 
whether spontaneously 
hypertensive (SH) rats may 
offer a better model of 
experimental bronchitis and 
Data showed that sulfur 
dioxide (SO2) exposure 
SH rats may yield a 
relevant experimental 
model of bronchitis 
 
Not applicable 




subsequent COPD phenotypes 
Wardlaw et al. (2005) 
[134] 
An article that discusses the 
use of a new taxonomy for 
mutli-dimensional phenotyping 
The authors suggest that 
development of this 
taxonomy will require a 
much more complete and 
sophisticated correlation of 
the many variables that 
uses complex statistical 




Not relevant machine 
learning methods under 
study 
Hackett et al. (2003) 
[135] 
A genetic study investigating 
the association between 
antioxidant-related genes and 
smoking-induced chronic 
bronchitis 
Data showed that 
antioxidant-related genes 
may be useful genetic 
markers in assessing 
susceptibility to smoking-
induced chronic bronchitis 
 
Not applicable 





Table 4. Data characteristics and methods for the identification of COPD phenotypes in the reviewed studies 
Study Data used in the clustering analysis Data reduction and clustering methods 
Yoon et al. (2019) 
[9] 
Age, BMI, smoking status, history of asthma, COPD 
assessment test (CAT) score, pre-bronchodilator 
FEV1 % predicted, diffusing capacity of carbon 
monoxide % predicted 
K-means 
Pikoula et al. 
(2019) [6] 
BMI, smoking status, atopy, GINA1 classification, 
eosinophilia, comorbidities 
Multiple correspondence analysis (MCA),   
k-means, and hierarchical clustering 
Kim et al. (2018) 
[10] 
BMI, Charlson comorbidity index, SGRQ2 total score, 
FEV1 
Factor analysis and hierarchical clustering 
Kim et al. (2017) 
[11] 
Clinical, physiological and imaging data PCA and hierarchical cluster analysis 
Burgel et. al. (2017) 
[8] 
Age, BMI, FEV1 % predicted, mMRC3 dyspnea 
scale, exacerbation in the past 12 months, 
comorbidities 
Factor analysis for mixed data (FAMD) and 
hierarchical clustering 
Peters et al. (2017) 
[14] 
FEV1 % predicted, BMI, exercise capacity, subjective 
symptoms, fatigue, quality of life 
Hierarchical and discriminant cluster 
analysis 
Chubachi et al. 
(2016) [17] 
Comorbidity data (e.g., cardiovascular diseases and 
diabetes)  
Hierarchical cluster analysis 
Fingleton et al. 
(2015) [19] 
Respiratory history and comorbidities, lung function, 
reversibility testing, biomarkers, disease control and 
health status  
Hierarchical cluster analysis 
Chen et al (2014) 
[16] 
Age, lung function (FEV1 % predicted), BMI, history 
of severe exacerbations, mMRC, SpO2, Charlson 
Index 
PCA, hierarchical, and k-means clustering 
Castaldi et al. 
(2014) [7] 
Demographic and clinical characteristics, spirometry, 
genome-wide SNP genotyping data, inspiratory and 
expiratory CT scans 
Factor analysis and k-means clustering 
Altenburg et al. 
(2012) [18] 
Age, BMI, quadriceps force, body plethysmography, 
exercise testing  
K-means cluster analysis 
Burgel et al. (2010) 
[12] 
Age, symptoms, spirometry, BMI, exacerbations, 
health and psychological status 
PCA and hierarchical cluster analysis 
Burgel et al. (2012) 
[13] 
Age, symptoms, health status, body 
plethysmography, DLCO4, CT scan, comorbidities 
PCA and hierarchical cluster analysis 
Garcia-Aymerich et 
al. (2011) [15] 
Symptoms, health status, body composition, 
plethysmography, CT scan, saliva and serum, 
exercise testing 
K-means cluster analysis 
1
GINA: Global Initiative for Asthma; 
2
SGRQ: St George’s Respiratory Questionnaire; 
3




 DLCO: Diffusing capacity of the lungs for carbon monoxide 
 
Table 5. Best practices recommended for the identification of clinically validated COPD phenotypes using clustering analysis 
Prospective 
longitudinal data 
External validation Large samples Handling of missing 
data 
Choice of variables and 
cluster analysis 
Use longitudinal 
prospective data over 
a long period of time 
from a large database 




from multiple settings 
(in different parts of 





response to therapy, 
mortality) 
Use large samples, 
ideally with more 




Through a combination of expert 
opinions, evidence-based data 
and literature reviews, data 





Figure 1. PRISMA diagram for the systematic review  
Records identified through database 
searching 






























 Additional records identified through 
other sources (e.g., hand-searching) 
(n = 34) 
Records after duplicates were removed 
(n = 113) 
Articles screened for title 
and abstract 
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Articles excluded 
(n = 65) 
Full-text articles assessed for 
eligibility 
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Full-text articles excluded  
(n = 34) 
Articles included in this 
review 
(n = 14) 
